The emerging role of antifolates in the treatment of malignant pleural mesothelioma

Seminars in Oncology

Volumn 29, Issue 1, 2002, Pages 77-81

  Fizazi, Karim ^a,b,c   John, William J ^a,b,c   Vogelzang, Nicholas J ^a,b,c  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b ELI LILLY AND COMPANY   (United States)

^c University of Chicago   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

10 PROPARGYL 5,8 DIDEAZAFOLIC ACID; 5,6 DIHYDROAZACITIDINE; CAPECITABINE; CARBOPLATIN; CISPLATIN; EDATREXATE; ETOPOSIDE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLIC ACID ANTAGONIST; FOLINIC ACID; METHOTREXATE; MITOMYCIN C; OXALIPLATIN; PEMETREXED; RALTITREXED; TRIMETREXATE;

BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; FEBRILE NEUTROPENIA; HUMAN; NEPHROTOXICITY; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; REVIEW; STOMATITIS;

EID: 0036179706     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.30233     Document Type: Article

References (48)

1. Continuing increase in mesothelioma mortality in Britain
2. The European mesothelioma epidemic
3. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy
4. Chemotherapy in malignant pleural mesothelioma. A review
5. A review of chemotherapy trials for malignant mesothelioma
6. Malignant pleural mesothelioma: A disease unaffected by current therapeutic maneuvers
7. Good symptom relief with palliative MVP (mitomycin C,vinblastine and cisplatin) chemotherapy in malignant mesothelioma
8. Phase II study of vinorelbine in patients with malignant pleural mesothelioma
9. Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma
10. Combination raltitrexed (Tomudex)-oxaliplatin: A step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma
11. High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234
12. Phase II study of paclitaxel (Taxol) and cisplatin (CDDP) in advanced pleural malignant mesothelioma (MM)
13. CPT-11 in malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B (CALGB 9733)
14. Phase I study of twice weekly 5-azacytidine (NSC-102816)
15. Diffuse malignant mesothelioma. Prospective evaluation in 69 patients
16. Phase II trial of 5,6-dihydro-5-azacytidine in pleural malignant mesothelioma
17. Dihydro-5-azacytidine in malignant mesothelioma
18. Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: A phase II study by the Cancer and Leukemia Group B
19. Chemotherapy of malignant mesothelioma
20. Malignant mesothelioma of pleura. Clinicopathologic observation
21. Chemotherapy of diffuse mesothelioma. Phase II trials of 5-fluorouracil and Adriamycin
22. A case report of malignant pleural mesothelioma with long-term disease control after chemotherapy
23. Response to chemotherapy of brain metastases from malignant pleural mesothelioma
24. A long-term survivor case of malignant mesothelioma treated by recombinant tumor necrosis factor-SAM2 (TNF-alpha mutein) and 5-fluorouracil (5-FU): A new therapeutic approach based on host-tumor relationship
25. A case of malignant peritoneal mesothelioma showed complete remission with chemotherapy
26. Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura
27. High dose methotrexate with citrouorum factor and vincristine in the treatment of malignant mesothelioma cancer
28. Response of mesothelioma to large doses of methotrexate with CF rescue (HDMTX-CF) used alone or woth cisplatinum
29. High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study
30. Phase II study of a novel antifolate, N10-propargyl-5,8 dideazafolic acid (CB3717), in malignant mesothelioma
31. Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B phase II study
32. Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B
33. Pemetrexed: A multitargeted antifolate agent with promising activity in solid tumors
34. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study
35. Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: Results from a phase II study
36. A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer
37. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin
38. Alimta in combination with carboplatin demonstrates clinical activity against malignant mesothelioma in a phase I trial
39. Phase II study of ALIMTA (pemetrexed disodium, MTA) single agent in patients with malignant pleural mesothelioma
40. MTA (LY231514): Relationship of vitamin metabolite profile, drug exposure, and other patient characteristics to toxicity
41. Vitamin B12 and folate reduce toxicity of Alimta (pemetrexed disodium, LY231514, MTA), a novel antifolate/antimetabolite
42. Folate-based thymidylate synthase inhibitors as anticancer drugs
43. Clinical pharmacokinetics of antitumor antifolates
44. Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors
45. A phase I, dose-finding and pharmacokinetic study of raltitrexed ('Tomudex') combined with oxaliplatin in patients with advanced cancer
46. The combination of raltitrexed ('Tomudex') and oxaliplatin is an active regimen in malignant mesothelioma: Results of a phase II study
47. Chimiothérapie par l'association raltitrexed-oxaliplatine chez des patients atteints de mésothéliome: Résultats réliminaires d'une étude de phase II
48. The alpha folate receptor is highly activated in malignant pleural mesothelioma